Fractyl Health, Inc. (GUTS)
NASDAQ: GUTS · Real-Time Price · USD
1.010
+0.026 (2.65%)
At close: Aug 13, 2025, 4:00 PM
1.020
+0.010 (0.99%)
Pre-market: Aug 14, 2025, 9:02 AM EDT
Fractyl Health Revenue
Fractyl Health had revenue of $17.00K in the twelve months ending June 30, 2025, down -85.71% year-over-year. In the year 2024, Fractyl Health had annual revenue of $93.00K, down -22.50%.
Revenue (ttm)
$17.00K
Revenue Growth
-85.71%
P/S Ratio
4,119.41
Revenue / Employee
$159
Employees
107
Market Cap
70.03M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
GUTS News
- 1 day ago - Fractyl Health, Inc. (GUTS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 6 days ago - Fractyl Health Announces Closing of $23 Million Underwritten Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares - GlobeNewsWire
- 7 days ago - Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference - GlobeNewsWire
- 8 days ago - Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering - GlobeNewsWire
- 8 days ago - Fractyl Health Announces Proposed Public Offering - GlobeNewsWire
- 8 days ago - Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita® Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure - GlobeNewsWire
- 4 weeks ago - Fractyl Health: Speculative Buy With Binary Risk - Seeking Alpha